Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Multinational, Active-controlled, (Open-labelled), Dose Finding, (Double-blinded), Parallel Group Trial Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin FlexPro) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency

Next Previous
Search
Trial Profile

A Randomised, Multinational, Active-controlled, (Open-labelled), Dose Finding, (Double-blinded), Parallel Group Trial Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin FlexPro) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Somapacitan (Primary) ; Somatropin
  • Indications Somatotropin deficiency
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms REAL 3
  • Sponsors Novo Nordisk

Most Recent Events

  • 11 Oct 2024 Status changed from recruiting to completed.
  • 18 Sep 2024 This trial has been completed in Slovenia ,according to the European Clinical Trials Database record.
  • 28 Oct 2023 This trial has been completed in Germany (Date of the global end of the trial: 02-Oct-2023), according to the European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top